http://saraswati.org.uk/programme/group-1-awakening-the-mind/ Update for the Week: Trying to Find the Bottom-Choppy Action But Tradeable XBI holds above $74.62 bottom up 1.3% for the week but can’t hold today’s gains. AMGN flat for the week at $193 but can’t hold gains at mid-week. Big winner TSRO up 64.9% for week now at $43. Tape looking better with more green […]
buy dapoxetine in singapore 11/16…TSRO Alert at $35, Up 32%, Company is for Sale 11/15p After Close…Traders: Rally is intact but needs another green day to confirm. Big mid-cap 4% movers today: AGIO ARNA (up 21.6%) ARRY CRSP LOXO NBIX ICPT SRPT XNCR We added small positions over the past week in ABBV AMRN KPTI QQQ XLV and XBI as […]
http://larryhefner.com/route-44-a-journey-chapter-4/ Update at Close 11/9/18 Remain Cautious as Rally Fails The NASDAQ down 1.6% and Russell 2000 down 1.8%, sold off killing hopes of a continued Post-Election rally. The biotech sector is for experienced traders only. The healthcare still looks good overall with the XLV down only 0.29% at $92.95. The XBI was crushed again down […]
Update 10/29 It’s a bear market in biotech so wait for the bottom. Have plenty of cash on hand. IBB at $102.77 down over 5% YTD. Clues: IJR and XBI need to bottom. ======= Update 10/27 Still on vacation, nothing to do . Impossible to trade or invest right now. Sentiment is crushed and numbers […]
Biotech Momentum Lost Technical Breakdown: XBI Near April Bottom but XLV Looks Good Market Looking for Growth from Large Cap Earnings 10 year auction has tepid demand at Yield of 3.225%, NASDAQ at 7602 own 1.75% (Prices as of mid-day 1:30 p EDT) Biotech momentum losses were triggered by a reversal in investor psychology because […]
Update 10/5/18 Very Weak Technicals after Biotech Sell-Off NASDAQ market closed off the lows down 1.16% at 7788. Biotech ETF IBB down 1.15% just above 3 month support of 116. Biotech ETF XBI down 1.51% at 90.45 broke downtrend line and May support at 92. More losers again but a several winners: e.g. BLUE,CRSP,IONS,RHHBY. Our […]
Update-10/1 Rally Fades Early Today…NASDAQ Moves to Red An early rally faded quickly today after an initial spike from new “NAFTA” deal. Biotech ETFs were red IBB down 0.63% and XBI down 1.34%. Mid-Cap biopharmas were mainly red with CAR-T and gene editing stocks hit hard: BLUE CRSP EDIT GWPH NTLA . Will provide news […]
Update 9/26: FED Rate Hike Curbs Traders but Biotech Rolls On The market dipped slightly then went red about 3:30P EDT resulting in a 0.4% loss for the Dow. Main rates will rise to the 2 to 2.25% level with more rate hikes in the future. During Trump’s Press Conference today he said he does not […]
Biotechs Bounce Back: Up From September Lows-Markets Surge Ahead XBI Up 1.66% to $97.16 up from 3 month tech support of $95;IBB up 1.39%. Broad rally brings Dow up 1%, S&P up 0.81% to fresh highs-strong 4 mo. trend line. Sector Winners: Tech (XLK) up 1.18%, Materials (XLB) up 1.08%, Healthcare (XLV) new high up […]
Update 9/19 : Lightened up on Abbvie (ABBV) in low 90s with news of CA lawsuit on Humira kickbacks. Amgen (AMGN) hits 52 week high in $204 range, strong hold up 14.9% YTD. GW Pharmaceuticals (GWPH) rallies 6.61% to $159 for second day on cannabis trading frenzy; up 18.7% YTD with market cap $4.5B vs […]
PO Box 3701
Manhattan Beach CA 90266
(310) 871-1231
rod@rayno.com
Rod Raynovich is the founder of Raygent Associates, a management consulting firm providing business development and strategic marketing services in the life science and medical device area. He publishes his thoughts and analysis on the biotech industry at www.raygent.com.